Inhibace Plus

Cilazapril, the active ingredient in Inhibace Plus, is an ACE inhibitor presented as an oral tablet for oral use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients by relaxing blood vessels and reducing fluid volume, thereby lowering elevated blood pressure and decreasing cardiovascular risk.

GNH USA supplies Inhibace Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inhibace Plus, containing an ACE inhibitor and a thiazide diuretic, is used in the management of hypertension.

- Essential hypertension: lowers systolic and diastolic blood pressure to target levels. - Stage 1 hypertension: helps achieve blood pressure control when monotherapy is insufficient. - Stage 2 hypertension: provides additional pressure reduction in patients requiring combination therapy.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Increased urination: due to diuretic effect. - Electrolyte disturbances: mild changes in potassium or sodium levels. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Severe dehydration: excessive fluid loss leading to low blood pressure. - Hyperkalemia: elevated potassium that may affect heart rhythm. - Acute renal impairment: sudden decline in kidney function. - Severe hypotension: dangerously low blood pressure. - Blood dyscrasias: rare blood cell abnormalities such as agranulocytosis.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Blood pressure monitoring: ensure adequate control and avoid excessive lowering. - Renal function assessment: check serum creatinine and eGFR periodically. - Electrolyte surveillance: monitor potassium and sodium levels, especially with concomitant drugs. - Pregnancy safety: avoid use in pregnancy due to known fetal risk (Category D). - Elderly patients: start at lower doses and watch for orthostatic hypotension. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Inhibace Plus may interact with several medicines; careful review is essential.

Major Interactions (Avoid): - Aliskiren: combined use can cause severe hypotension and renal dysfunction. - Potassium‑sparing diuretics or supplements: increase risk of hyperkalemia. - Lithium: may raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function. - Other antihypertensives (beta‑blockers, calcium channel blockers): may cause additive blood pressure lowering. - Diuretics causing electrolyte loss: monitor sodium and potassium levels closely.